NCT03216278View on ClinicalTrials.gov

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

May 22, 2018

Study Completion Date

May 22, 2018

Conditions
Healthy Subjects in Fasted and Fed State
Interventions
DRUG

Dapagliflozin/metformin XR 5/500mg

Tablets for oral administration, once daily, once per treatment period

DRUG

Dapagliflozin/metformin XR 5/500 mg

Tablets for oral administration, once daily, once per treatment period

DRUG

Dapagliflozin/metformin XR 5/500mg

Tablets for oral administration, once daily, once per treatment period

DRUG

Dapagliflozin/metformin XR 5/500mg

Tablets for oral administration, once daily, once per treatment period

DRUG

Dapagliflozin/metformin XR 10/1000mg

Tablets for oral administration, once daily, once per treatment period

DRUG

Dapagliflozin/metformin XR 10/1000mg

Tablets for oral administration, once daily, once per treatment period

DRUG

Dapagliflozin/metformin XR 10/1000mg

Tablets for oral administration, once daily, once per treatment period

DRUG

Dapagliflozin/metformin XR 10/1000mg

Tablets for oral administration, once daily, once per treatment period

Trial Locations (1)

74935-530

Research Site, Aparecida de Goiânia

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY